.png)
Branded Generics Market by Application - Global Industry Analysis & Forecast to 2027
Published On : September 2019 Pages : 170 Category: Pharmaceuticals Report Code : HC095558
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Branded Generics Market by Application (Cardiovascular, CNS, Anti-Cancer, Anti-Infective) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The branded generics market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. A branded conventional is the brand name given to a medication that is bioequivalent to the first (trend-setter) brand, however, once the first brand has fallen off patent it is showcased under another organization's brand name, not the generic name. Some branded generics are exceptionally made as novel dose types of off-patent medications, filling in a measurement gap while offering buyers a name that is likely simpler to recall than the genuine nonexclusive name. Marked generics are a little, yet beneficial fragment of the pharmaceutical market.
Drivers and Restraints
The worldwide branded generics market is anticipated to develop step by step as huge number of pharmaceutical items will go off patent within the forecast period. The worldwide branded generics market is unsurprising to develop altogether as enormous number of pharmaceutical items will be off patent within the forecast period. Straightforward promoting approval strategies, entry of new players, changing medication rehearses, more prominent net revenue are some different components which are anticipated to build the worldwide branded generics market. Though, enormous challenge from branded drugs and commodity generic products may hamper the growth of branded generics market
Regional Insights
Among the geographies, North America is expected to dominate the branded generics market. Growing demand for cost-effective medicines in the region contribute to the growth of branded generics market.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Teva Pharmaceutical Industries Ltd
- AstraZeneca
- Sandoz
- Mylan N.V.
- Sanofi
- Hospira Inc.
- ZydusCadila
- Lupin Pharmaceuticals, Inc.
- Valeant
- Apotex Inc.
- GlaxoSmithKline Pharmaceuticals Limited
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Branded Generics Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
o Cardiovascular
o CNS
o Anti-Cancer
o Anti-Infective
· Branded Generics Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Teva Pharmaceutical Industries Ltd
o AstraZeneca
o Sandoz
o Mylan N.V.
o Sanofi
o Hospira Inc.
o ZydusCadila
o Lupin Pharmaceuticals, Inc.
o Valeant
o Apotex Inc.
o GlaxoSmithKline Pharmaceuticals Limited
· Branded Generics Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Branded Generics Market, By Country
o U.S. Branded Generics Market
o Canada Branded Generics Market
o Mexico Branded Generics Market
o Europe
§ Europe Branded Generics Market, By Country
· Germany Branded Generics Market
o UK Branded Generics Market
o France Branded Generics Market
o Russia Branded Generics Market
o Italy Branded Generics Market
o Rest of Europe Branded Generics Market
o Asia-Pacific
§ Asia-Pacific Branded Generics Market, By Country
o China Branded Generics Market
o Japan Branded Generics Market
o South Korea Branded Generics Market
o India Branded Generics Market
o Southeast Asia Branded Generics Market
o Rest of Asia-Pacific Branded Generics Market
o South America
§ South America Branded Generics Market
o Brazil Branded Generics Market
o Argentina Branded Generics Market
o Columbia Branded Generics Market
o Rest of South America Branded Generics Market
o Middle East and Africa
§ Middle East and Africa Branded Generics Market
o Saudi Arabia Branded Generics Market
o UAE Branded Generics Market
o Egypt Branded Generics Market
o Nigeria Branded Generics Market
o South Africa Branded Generics Market
o Rest of MEA Branded Generics Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Branded Generics Market, By Application
5.1. Introduction
5.2. Global Branded Generics Revenue and Market Share by Application (2017-2027)
5.2.1. Global Branded Generics Revenue and Revenue Share by Application (2017-2027)
5.3. Cardiovascular
5.3.1. Global Cardiovascular Revenue and Growth Rate (2017-2027)
5.4. CNS
5.4.1. Global CNS Revenue and Growth Rate (2017-2027)
5.5. Anti-Cancer
5.5.1. Global Anti-Cancer Revenue and Growth Rate (2017-2027)
5.6. Anti-Infective
5.6.1. Global Anti-Infective Revenue and Growth Rate (2017-2027)
6. Branded Generics Market, By Region
6.1. Introduction
6.2. Global Branded Generics Revenue and Market Share by Regions
6.2.1. Global Branded Generics Revenue by Regions (2017-2027)
6.3. North America Branded Generics by Countries
6.3.1. North America Branded Generics Revenue and Growth Rate (2017-2027)
6.3.2. North America Branded Generics Revenue (Million USD) by Countries (2017-2027)
6.3.3. United States
6.3.3.1. United States Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.4. Canada
6.3.4.1. Canada Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.5. Mexico
6.3.5.1. Mexico Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4. Europe Branded Generics by Countries
6.4.1. Europe Branded Generics Revenue and Growth Rate (2017-2027)
6.4.2. Europe Branded Generics Revenue (Million USD) by Countries (2017-2027)
6.4.3. Germany
6.4.3.1. Germany Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.4. France
6.4.4.1. France Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.5. UK
6.4.5.1. UK Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.6. Russia
6.4.6.1. Russia Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.7. Italy
6.4.7.1. Italy Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5. Asia-Pacific Branded Generics by Countries
6.5.1. Asia-Pacific Branded Generics Revenue and Growth Rate (2017-2027)
6.5.2. Asia-Pacific Branded Generics Revenue (Million USD) by Countries (2017-2027)
6.5.3. China
6.5.3.1. China Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.4. Japan
6.5.4.1. Japan Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.5. Korea
6.5.5.1. Korea Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.6. India
6.5.6.1. India Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.7. Southeast Asia
6.5.7.1. Southeast Asia Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.8. Rest of Asia-Pacific
6.5.8.1. Rest of Asia-Pacific Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.6. South America Branded Generics by Countries
6.6.1. South America Branded Generics Revenue and Growth Rate (2017-2027)
6.6.2. South America Branded Generics Revenue (Million USD) by Countries (2017-2027)
6.6.3. Brazil
6.6.3.1. Brazil Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.4. Argentina
6.6.4.1. Argentina Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.5. Columbia
6.6.5.1. Columbia Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.6. Rest of South America
6.6.6.1. Rest of South America Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7. Middle East and Africa Branded Generics by Countries
6.7.1. Middle East and Africa Branded Generics Revenue and Growth Rate (2017-2027)
6.7.2. Middle East and Africa Branded Generics Revenue (Million USD) by Countries (2017-2027)
6.7.3. Saudi Arabia
6.7.3.1. Saudi Arabia Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.4. United Arab Emirates
6.7.4.1. United Arab Emirates Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.5. Egypt
6.7.5.1. Egypt Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.6. Nigeria
6.7.6.1. Nigeria Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.7. South Africa
6.7.7.1. South Africa Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.8. Turkey
6.7.8.1. Turkey Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.9. Rest of Middle East and Africa
6.7.9.1. Rest of Middle East and Africa Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
7. Company Profiles
7.1. Teva Pharmaceutical Industries Ltd
7.1.1. Business Overview
7.1.2. Service Portfolio
7.1.3. Strategic Developments
7.1.4. Financial Overview
7.2. AstraZeneca
7.2.1. Business Overview
7.2.2. Service Portfolio
7.2.3. Strategic Developments
7.2.4. Financial Overview
7.3. Sandoz
7.3.1. Business Overview
7.3.2. Service Portfolio
7.3.3. Strategic Developments
7.3.4. Financial Overview
7.4. Mylan N.V.
7.4.1. Business Overview
7.4.2. Service Portfolio
7.4.3. Strategic Developments
7.4.4. Financial Overview
7.5. Sanofi
7.5.1. Business Overview
7.5.2. Service Portfolio
7.5.3. Strategic Developments
7.5.4. Financial Overview
7.6. Hospira Inc.
7.6.1. Business Overview
7.6.2. Service Portfolio
7.6.3. Strategic Developments
7.6.4. Financial Overview
7.7. ZydusCadila
7.7.1. Business Overview
7.7.2. Service Portfolio
7.7.3. Strategic Developments
7.7.4. Financial Overview
7.8. Lupin Pharmaceuticals, Inc.
7.8.1. Business Overview
7.8.2. Service Portfolio
7.8.3. Strategic Developments
7.8.4. Financial Overview
7.9. Valeant
7.9.1. Business Overview
7.9.2. Service Portfolio
7.9.3. Strategic Developments
7.9.4. Financial Overview
7.10. Apotex Inc.
7.10.1. Business Overview
7.10.2. Service Portfolio
7.10.3. Strategic Developments
7.10.4. Financial Overview
7.11. GlaxoSmithKline Pharmaceuticals Limited
7.11.1. Business Overview
7.11.2. Service Portfolio
7.11.3. Strategic Developments
7.11.4. Financial Overview
8. Branded Generics Market Forecast (2017-2027)
8.1. Global Branded Generics Revenue (Millions USD) and Growth Rate (2017-2027)
8.2. Branded Generics Market Forecast by Regions (2017-2027)
8.2.1. North America Branded Generics Market Forecast (2017-2027)
8.2.1.1. United States Branded Generics Market Forecast (2017-2027)
8.2.1.2. Canada Branded Generics Market Forecast (2017-2027)
8.2.1.3. Mexico Branded Generics Market Forecast (2017-2027)
8.2.2. Europe Branded Generics Market Forecast (2017-2027)
8.2.2.1. Germany Branded Generics Market Forecast (2017-2027)
8.2.2.2. France Branded Generics Market Forecast (2017-2027)
8.2.2.3. UK Branded Generics Market Forecast (2017-2027)
8.2.2.4. Russia Branded Generics Market Forecast (2017-2027)
8.2.2.5. Italy Branded Generics Market Forecast (2017-2027)
8.2.2.6. Rest of Europe Branded Generics Market Forecast (2017-2027)
8.2.3. Asia-Pacific Branded Generics Market Forecast (2017-2027)
8.2.3.1. China Branded Generics Market Forecast (2017-2027)
8.2.3.2. Japan Branded Generics Market Forecast (2017-2027)
8.2.3.3. Korea Branded Generics Market Forecast (2017-2027)
8.2.3.4. India Branded Generics Market Forecast (2017-2027)
8.2.3.5. Southeast Asia Branded Generics Market Forecast (2017-2027)
8.2.3.6. Rest of Asia-Pacific Branded Generics Market Forecast (2017-2027)
8.2.4. South America Branded Generics Market Forecast (2017-2027)
8.2.4.1. Brazil Branded Generics Market Forecast (2017-2027)
8.2.4.2. Argentina Branded Generics Market Forecast (2017-2027)
8.2.4.3. Columbia Branded Generics Market Forecast (2017-2027)
8.2.4.4. Rest of South America Branded Generics Market Forecast (2017-2027)
8.2.5. Middle East and Africa Branded Generics Market Forecast (2017-2027)
8.2.5.1. Saudi Arabia Branded Generics Market Forecast (2017-2027)
8.2.5.2. United Arab Emirates Branded Generics Market Forecast (2017-2027)
8.2.5.3. Egypt Branded Generics Market Forecast (2017-2027)
8.2.5.4. Nigeria Branded Generics Market Forecast (2017-2027)
8.2.5.5. South Africa Branded Generics Market Forecast (2017-2027)
8.2.5.6. Turkey Branded Generics Market Forecast (2017-2027)
8.2.5.7. Rest of Middle East and Africa Branded Generics Market Forecast (2017-2027)
8.3. Branded Generics Market Forecast by Application (2017-2027)
8.3.1. Branded Generics Forecast by Application (2017-2027)
8.3.2. Branded Generics Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Branded Generics Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Branded Generics Revenue and Revenue Share by Application (2017-2018)
Figure Global Cardiovascular Revenue and Growth Rate (2017-2018)
Figure Global CNS Revenue and Growth Rate (2017-2018)
Figure Global Anti-Cancer Revenue and Growth Rate (2017-2018)
Figure Global Anti-Infective Revenue and Growth Rate (2017-2018)
Table Global Branded Generics Revenue by Regions (2017-2018)
Figure North America Branded Generics Growth Rate (2017-2018)
Figure North America Branded Generics Revenue and Growth Rate (2017-2018)
Figure North America Branded Generics by Countries (2017-2018)
Figure North America Branded Generics Revenue (Million USD) by Countries (2017-2018)
Figure United States Branded Generics Growth Rate (2017-2018)
Figure United States Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Branded Generics Growth Rate (2017-2018)
Figure Canada Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Branded Generics Growth Rate (2017-2018)
Figure Mexico Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Branded Generics Growth Rate (2017-2018)
Figure Europe Branded Generics Revenue and Growth Rate (2017-2018)
Figure Europe Branded Generics by Countries (2017-2018)
Figure Europe Branded Generics Revenue (Million USD) by Countries (2017-2018)
Figure Germany Branded Generics Growth Rate (2017-2018)
Figure Germany Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Branded Generics Growth Rate (2017-2018)
Figure France Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Branded Generics Growth Rate (2017-2018)
Figure UK Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Branded Generics Growth Rate (2017-2018)
Figure Russia Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Branded Generics Growth Rate (2017-2018)
Figure Italy Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Branded Generics Growth Rate (2017-2018)
Figure Rest of Europe Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Branded Generics Growth Rate (2017-2018)
Figure Asia-Pacific Branded Generics Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Branded Generics by Countries (2017-2018)
Figure Asia-Pacific Branded Generics Revenue (Million USD) by Countries (2017-2018)
Figure China Branded Generics Growth Rate (2017-2018)
Figure China Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Branded Generics Growth Rate (2017-2018)
Figure Japan Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Branded Generics Growth Rate (2017-2018)
Figure Korea Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Branded Generics Growth Rate (2017-2018)
Figure India Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Branded Generics Growth Rate (2017-2018)
Figure Southeast Asia Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Branded Generics Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Branded Generics Growth Rate (2017-2018)
Figure South America Branded Generics Revenue and Growth Rate (2017-2018)
Figure South America Branded Generics by Countries (2017-2018)
Figure South America Branded Generics Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Branded Generics Growth Rate (2017-2018)
Figure Brazil Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Branded Generics Growth Rate (2017-2018)
Figure Argentina Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Branded Generics Growth Rate (2017-2018)
Figure Columbia Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Branded Generics Growth Rate (2017-2018)
Figure Rest of South America Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Branded Generics Growth Rate (2017-2018)
Figure Middle East and Africa Branded Generics Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Branded Generics by Countries (2017-2018)
Figure Middle East and Africa Branded Generics Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Branded Generics Growth Rate (2017-2018)
Figure Saudi Arabia Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Branded Generics Growth Rate (2017-2018)
Figure United Arab Emirates Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Branded Generics Growth Rate (2017-2018)
Figure Egypt Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Branded Generics Growth Rate (2017-2018)
Figure Nigeria Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Branded Generics Growth Rate (2017-2018)
Figure South Africa Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Branded Generics Growth Rate (2017-2018)
Figure Turkey Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Branded Generics Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Branded Generics Revenue (Millions USD) and Growth Rate (2017-2018)
Table Teva Pharmaceutical Industries Ltd Branded Generics Financial Overview
Table AstraZeneca Branded Generics Financial Overview
Table Sandoz Branded Generics Financial Overview
Table Mylan N.V. Branded Generics Financial Overview
Table Sanofi Branded Generics Financial Overview
Table Hospira Inc. Branded Generics Financial Overview
Table ZydusCadila Branded Generics Financial Overview
Table Lupin Pharmaceuticals, Inc. Branded Generics Financial Overview
Table Valeant Branded Generics Financial Overview
Table Apotex Inc. Branded Generics Financial Overview
Table GlaxoSmithKline Pharmaceuticals Limited Branded Generics Financial Overview
Figure Global Branded Generics Revenue (Millions USD) and Growth Rate (2018-2025)
Table Branded Generics Market Forecast by Regions (2018-2025)
Figure North America Branded Generics Market Forecast (2018-2025)
Figure United States Branded Generics Market Forecast (2018-2025)
Figure Canada Branded Generics Market Forecast (2018-2025)
Figure Mexico Branded Generics Market Forecast (2018-2025)
Figure Europe Branded Generics Market Forecast (2018-2025)
Figure Germany Branded Generics Market Forecast (2018-2025)
Figure France Branded Generics Market Forecast (2018-2025)
Figure UK Branded Generics Market Forecast (2018-2025)
Figure Russia Branded Generics Market Forecast (2018-2025)
Figure Italy Branded Generics Market Forecast (2018-2025)
Figure Rest of Europe Branded Generics Market Forecast (2018-2025)
Figure Asia-Pacific Branded Generics Market Forecast (2018-2025)
Figure China Branded Generics Market Forecast (2018-2025)
Figure Japan Branded Generics Market Forecast (2018-2025)
Figure Korea Branded Generics Market Forecast (2018-2025)
Figure India Branded Generics Market Forecast (2018-2025)
Figure Southeast Asia Branded Generics Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Branded Generics Market Forecast (2018-2025)
Figure South America Branded Generics Market Forecast (2018-2025)
Figure Brazil Branded Generics Market Forecast (2018-2025)
Figure Argentina Branded Generics Market Forecast (2018-2025)
Figure Columbia Branded Generics Market Forecast (2018-2025)
Figure Rest of South America Branded Generics Market Forecast (2018-2025)
Figure Middle East and Africa Branded Generics Market Forecast (2018-2025)
Figure Saudi Arabia Branded Generics Market Forecast (2018-2025)
Figure United Arab Emirates Branded Generics Market Forecast (2018-2025)
Figure Egypt Branded Generics Market Forecast (2018-2025)
Figure Nigeria Branded Generics Market Forecast (2018-2025)
Figure South Africa Branded Generics Market Forecast (2018-2025)
Figure Turkey Branded Generics Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Branded Generics Market Forecast (2018-2025)
Figure Global Branded Generics Forecast by Application (2018-2025)
Figure Global Branded Generics Market Share Forecast by Application (2018-2025)
Figure Global Branded Generics Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|